{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:34:35Z","timestamp":1760232875193,"version":"build-2065373602"},"reference-count":26,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"Okogen, Pty Ltd., NIH Core Grant for Vision Research","doi-asserted-by":"publisher","award":["EY08098"],"award-info":[{"award-number":["EY08098"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Eye &amp; Ear Foundation of Pittsburgh","award":["EY08098"],"award-info":[{"award-number":["EY08098"]}]},{"name":"University of Pittsburgh Department of Ophthalmology from Research to Prevent Blindness","award":["EY08098"],"award-info":[{"award-number":["EY08098"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Adenovirus ocular infections are common ocular viral infections seen worldwide, for which there is no approved antiviral therapy available. Ranpirnase is a novel ribonuclease which preferentially degrades tRNA resulting in an inhibition of protein synthesis. The study goal was to determine the anti-adenoviral activity of topical formulations of ranpirnase (OKG-0301) on adenoviral replication in the Ad5\/NZW rabbit ocular replication model. NZW rabbits were inoculated in both eyes with human adenovirus type 5 (HAdV5) after corneal scarification. A day later, topical therapy was initiated in both eyes with 0.03% OKG-0301, 0.003% OKG-0301, saline or 0.5% cidofovir. Eyes were cultured to determine HAdV5 eye titers over 2 weeks. OKG-0301 (0.03% and 0.003%) and 0.5% cidofovir decreased viral titers compared to saline. Furthermore, both OKG-0301 formulations and 0.5% cidofovir shortened the duration of the HAdV5 infection compared to saline. Both 0.03% OKG-0301 and 0.003% OKG-0301 demonstrated increased antiviral activity compared to saline in the Ad5\/NZW rabbit ocular replication model. The antiviral activity of the OKG-0301 groups was similar to that of the positive antiviral control, 0.5% cidofovir. Ranpirnase (OKG-0301) may be a potential candidate for a topical antiviral for adenoviral eye infections. Further clinical development is warranted.<\/jats:p>","DOI":"10.3390\/pathogens11121485","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T01:47:46Z","timestamp":1670377666000},"page":"1485","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ranpirnase (OKG-0301), a Novel Ribonuclease, Demonstrates Antiviral Activity against Adenovirus in the Ad5\/NZW Rabbit Ocular Replication Model"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4246-3276","authenticated-orcid":false,"given":"Eric G.","family":"Romanowski","sequence":"first","affiliation":[{"name":"The Charles T. Campbell Ophthalmic Microbiology Laboratory, UPMC Eye Center, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen A.","family":"Yates","sequence":"additional","affiliation":[{"name":"The Charles T. Campbell Ophthalmic Microbiology Laboratory, UPMC Eye Center, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J.","family":"Daniels","sequence":"additional","affiliation":[{"name":"Okogen Pty Ltd., Melbourne, VIC 3000, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian M.","family":"Strem","sequence":"additional","affiliation":[{"name":"Okogen Pty Ltd., Melbourne, VIC 3000, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E.","family":"Romanowski","sequence":"additional","affiliation":[{"name":"The Charles T. Campbell Ophthalmic Microbiology Laboratory, UPMC Eye Center, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8558-0782","authenticated-orcid":false,"given":"Regis P.","family":"Kowalski","sequence":"additional","affiliation":[{"name":"The Charles T. Campbell Ophthalmic Microbiology Laboratory, UPMC Eye Center, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.survophthal.2015.04.001","article-title":"Adenoviral keratoconjunctivitis","volume":"60","author":"Jhanji","year":"2015","journal-title":"Surv. Ophthalmol."},{"key":"ref_2","first-page":"4135","article-title":"Topical HPMPC inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model","volume":"35","author":"Gordon","year":"1994","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_3","first-page":"460","article-title":"Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model","volume":"41","author":"Romanowski","year":"2000","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5295","DOI":"10.1167\/iovs.08-3286","article-title":"The in vitro and in vivo evaluation of ddC as a topical antiviral for ocular adenovirus infections","volume":"50","author":"Romanowski","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Romanowski, E.G., Hussein, I.T.M., Cardinale, S.C., Butler, M.M., Morin, L.R., Bowlin, T.L., Yates, K.A., Shanks, R.M.Q., and Kowalski, R.P. (2021). Filociclovir is an active antiviral agent against ocular adenovirus isolates In Vitro and in the Ad5\/NZW rabbit ocular model. Pharmaceuticals, 14.","DOI":"10.3390\/ph14040294"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/00003226-199409000-00011","article-title":"Activity of ganciclovir against human adenovirus type-5 infection in cell culture and cotton rat eyes","volume":"13","author":"Trousdale","year":"1994","journal-title":"Cornea"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1167\/iovs.05-1270","article-title":"N\u2013Chlorotaurine is an effective antiviral agent against adenovirus in vitro and in the Ad5\/NZW rabbit ocular model","volume":"47","author":"Romanowski","year":"2006","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/jop.2011.0082","article-title":"Treatment of epidemic keratoconjunctivitis with 2% povidone-iodine: A pilot study","volume":"28","author":"Trinavarat","year":"2012","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1167\/iovs.10-5944","article-title":"Clinical and antiviral efficacy of an ophthalmic formulation of dexamethasone povidone-iodine in a rabbit model of adenoviral keratoconjunctivitis","volume":"52","author":"Clement","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1167\/iovs.07-0491","article-title":"Efficacy of topical immunoglobulins (IG) against experimental adenoviral ocular infection","volume":"48","author":"Nwanegbo","year":"2007","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Romanowski, E.G., Yates, K.A., Paull, J.R.A., Heery, G.P., and Shanks, R.M.Q. (2021). Topical astodrimer sodium, a non-toxic polyanionic dendrimer, demonstrates antiviral activity in an experimental ocular adenovirus infection model. Molecules, 26.","DOI":"10.3390\/molecules26113419"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00063030-200822010-00006","article-title":"Ribonucleases as novel chemotherapeutics. The ranpirnase example","volume":"22","author":"Lee","year":"2008","journal-title":"Biodrugs"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Smith, T.G., Jackson, F.R., Morgan, C.N., Carson, W.C., Martin, B.E., Gallardo-Romero, N., Ellison, J.A., Greenberg, L., Hodge, T., and Squiquera, L. (2020). Antiviral ranpirnase TMR-001 inhibits rabies virus release and cell-to-cell infection In Vitro. Viruses, 12.","DOI":"10.3390\/v12020177"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"11692","DOI":"10.18632\/oncotarget.14302","article-title":"Activating transcription factor 3 is crucial for antitumor activity and to strengthen the antiviral properties of Onconase","volume":"8","author":"Vert","year":"2017","journal-title":"Oncotarget"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"20783","DOI":"10.1074\/jbc.271.34.20783","article-title":"Inhibition of HIV-1 production and selective degradation of viral RNA by an amphibian ribonuclease","volume":"271","author":"Saxena","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1089\/aid.2017.0308","article-title":"Ranpirnase Reduces HIV-1 Infection and Associated Inflammatory Changes in a Human Colorectal Explant Model","volume":"34","author":"Brand","year":"2018","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3851\/IMP3133","article-title":"Ranpirnase eradicates human papillomavirus in cultured cells and heals anogenital warts in a Phase I study","volume":"22","author":"Squiquera","year":"2017","journal-title":"Antivir. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.antiviral.2016.06.009","article-title":"Antiviral effect of ranpirnase against Ebola virus","volume":"132","author":"Hodge","year":"2016","journal-title":"Antivir. Res."},{"key":"ref_19","unstructured":"Baron, E.J., and Finegold, S.M. (1990). Laboratory methods in basic virology. Baily and Scott\u2019s Diagnostic Microbiology, CV Mosby Company. [8th ed.]."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1167\/iovs.12-9656","article-title":"Analysis of human adenovirus type 19 associated with epidemic keratoconjunctivitis and its reclassification as adenovirus type 64","volume":"53","author":"Zhou","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_21","first-page":"532","article-title":"Multiple adenoviral serotypes demonstrate host range extension in the New Zealand rabbit ocular model","volume":"39","author":"Romanowski","year":"1998","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1134\/S0026893314040050","article-title":"Ribonucleases as antiviral agents","volume":"48","author":"Ilinskaya","year":"2014","journal-title":"Mol. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/archneur.1976.00500090004002","article-title":"Ribonuclease treatment of tick-borne encephalitis","volume":"33","author":"Glukhov","year":"1976","journal-title":"Arch. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12985-017-0915-1","article-title":"Bacterial ribonuclease binase exerts an intra-cellular anti-viral mode of action targeting viral RNAs in influenza a virus-infected MDCK-II cells","volume":"15","author":"Mostafa","year":"2018","journal-title":"Virol. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"15142","DOI":"10.1074\/jbc.M108115200","article-title":"Entry into cells and selective degradation of tRNA by a cytotoxic member of the RNase A family","volume":"277","author":"Saxena","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_26","unstructured":"Watson, S.L., Casson, R., Tay-Kearney, M.-L., Daniels, E.J., Strem, B.M., Giles, P., Verma, N., Liebenberg, N., Bloom, H., and Faigenbaum, F. (2021, January 1\u20137). Acute adenoviral conjunctivitis treatment: A Phase 2 interim analysis of OKG-0301. Proceedings of the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Virtual. Abstract 404."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/11\/12\/1485\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:35:23Z","timestamp":1760146523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/11\/12\/1485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,7]]},"references-count":26,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["pathogens11121485"],"URL":"https:\/\/doi.org\/10.3390\/pathogens11121485","relation":{},"ISSN":["2076-0817"],"issn-type":[{"type":"electronic","value":"2076-0817"}],"subject":[],"published":{"date-parts":[[2022,12,7]]}}}